IL-26 and Systemic Lupus Erythematosus
IL-26 and Systemic Lupus Erythematosus
Treatment of multisystemic forms of lupus displays severe side effects and limited efficacy,
 underscoring the need to better dissection of the pathogenic mechanisms. Concordant with
 preliminary data, IL26 signaling could be impaired in systemic lupus. Moreover, IL 26 could
 be a marker of the disease activity and then a potential therapeutic target. In the present
 study, serum IL 26 level in lupus patients and control will be measured.
Inclusion Criteria:

 -  diagnostic of Lupus according to ACR criteria ( four criteria are necessary)

 -  age > 18 years old

 Exclusion Criteria:

 -  treatment by cyclophosphamide, rituximab, belimumab in the year before inclusion study